Molecular Therapeutics

Type: Company
Name: Molecular Therapeutics
First reported Sep 10 2014 - Updated Sep 10 2014 - 2 reports

Data on Molecular Therapeutics Reported by Researchers at Aarhus University (Managing microRNAs with vector-encoded decoy-type inhibitors)

By a News Reporter-Staff News Editor at Gene Therapy Weekly -- Current study results on Biotechnology have been published. According to news originating from Aarhus, Denmark, by NewsRx correspondents, research stated, "A rapidly growing understanding ... [Published Industrial Info Financials - Sep 10 2014]
First reported Sep 10 2014 - Updated Sep 10 2014 - 1 reports

Less pain, more gain

JUPITER, Fla.—While keeping its focus on finding a cure, scientists from the Florida campus of have discovered new targets for potentially increasing the effectiveness of current treatments for breast cancer and reducing the undesirable side effects. ... [Published Drug Discovery News - Sep 10 2014]
First reported Sep 02 2014 - Updated Sep 02 2014 - 1 reports

uniQure Announces Results for the Second Quarter and First Half of 2014 and Provides Update on Gene Therapy Programs

AMSTERDAM, the Netherlands, Sept. 2, 2014 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq:QURE), a leader in human gene therapy, today announced results for the second quarter of 2014 and an update on multiple gene therapy programs.Corporate HighlightsIn July, ... [Published Virtual Strategy Magazine - Sep 02 2014]
First reported Aug 28 2014 - Updated Aug 28 2014 - 2 reports

Reports from Osaka University Provide New Insights into Molecular Therapeutics (Evidence of the Survival of Ectopically Transplanted Oral Mucosal...

Reports from Osaka University Provide New Insights into Molecular Therapeutics (Evidence of the Survival of Ectopically Transplanted Oral Mucosal Epithelial Stem Cells After Repeated Wounding of Cornea) By a News Reporter-Staff News Editor at Biotech ... [Published Crawford Financial Planning - Aug 28 2014]
First reported Aug 28 2014 - Updated Aug 28 2014 - 2 reports

Research Data from Tohoku University Update Understanding of Molecular Therapeutics (Restoration of the Majority of the Visual Spectrum by Using...

Research Data from Tohoku University Update Understanding of Molecular Therapeutics (Restoration of the Majority of the Visual Spectrum by Using Modified Volvox Channelrhodopsin-1) By a News Reporter-Staff News Editor at Gene Therapy Weekly -- A new study ... [Published Wall Street Business Network - Aug 28 2014]
First reported Aug 19 2014 - Updated Aug 19 2014 - 1 reports

4-Aminopyridyl-Based CYP51 Inhibitors as Anti-Trypanosoma cruzi Drug Leads with Improved Pharmacokinetic Profile and in Vivo Potency

†Center for Discovery and Innovation in Parasitic Diseases, ‡Department of Pathology and §Department of Medicine, Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, California 94158, United States Cellular Ultra-Structure ... [Published Journal of Medicinal Chemistry - Aug 19 2014]
First reported Aug 12 2014 - Updated Aug 12 2014 - 1 reports

Research Leader Looks Beyond Genetic Mechanisms of Acquired Resistance to TKI Therapies

Jeff Settleman, PhDJeff Settleman, PhD, oversees efforts to identify and validate targets for oncology drug discovery and to discover predictive biomarkers for new cancer therapies. Prior to joining Genentech, Settleman spent 18 years on the faculty at ... [Published OncLive - Aug 12 2014]
First reported Aug 11 2014 - Updated Aug 12 2014 - 2 reports

Oncothyreon Announces Acquisition of Alpine Biosciences

Oncothyreon to Leverage Alpine's Protocell Technology to Enable Targeted Delivery of Molecular Therapeutics for Serious DiseasesCompany to Hold Conference Call at 4:30 p.m. EDT Today SEATTLE, WA, Aug. 11, 2014 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ... [Published TickerTech.com - Aug 11 2014]
First reported Aug 11 2014 - Updated Aug 11 2014 - 2 reports

Ignyta Appoints Adrian Senderowicz, M.D., as Chief Medical Officer and Senior Vice President, Clinical Development and Regulatory Affairs

SAN DIEGO--(BUSINESS WIRE)-- Ignyta, Inc. (Nasdaq: RXDX), an oncology precision medicine biotechnology company, announced today that Adrian Senderowicz, M.D., has been appointed as Chief Medical Officer and Senior Vice President, Clinical Development ... [Published Investor's Business Daily - Aug 11 2014]
First reported Apr 21 2014 - Updated Apr 22 2014 - 1 reports

HERS Breast Cancer Foundation Event Honors Community Leadership in...

The fifth annual People with Purpose Awards Luncheon on April 24 recognizes the contributions of local nonprofits, business leaders, and doctors in support of breast cancer survivors. HERS Breast Cancer Foundation today announced that they are hosting ... [Published PRWeb - Apr 21 2014]

Quotes

...According to news originating from Aarhus, Denmark, by NewsRx correspondents, research stated, "A rapidly growing understanding of the complex circuitry of microRNA (miRNA)-mediated gene regulation is attracting attention to miRNAs as new drug targets...."
Our news journalists obtained a quote from the research from Aarhus University , "Such synthetic miRNA inhibitors have reached the clinic with remarkable pace and may soon appear as new therapeutic modalities in several diseases. Shortcomings, however, include high production costs, the requirement for repeated administration, and difficulty achieving tissue-specific delivery. With the many recent landmark achievements in clinical gene therapy, new and refined vector-encoded miRNA suppression technologies are attractive for many applications, not least as tools in innumerable daily studies of miRNA biology in laboratories worldwide. Here, we provide an overview of the strategies that have been used to adapt vector-encoded inhibitors for miRNA suppression and discuss advantages related to spatiotemporal and long-term miRNA attenuation. With the remarkable new discovery of miRNA management by naturally occurring circular RNAs, RNA circles generated by trans-splicing mechanisms may prove to be well-suited carriers of decoy-type miRNA inhibitors."
...According to news originating from Osaka, Japan , by NewsRx correspondents, research stated, "Tissue engineering has become an essential tool in the development of regenerative medicine. We have developed cell sheet based techniques for use in regenerative medicine that have already been successfully used in clinical applications."
...According to news originating from Miyagi, Japan , by NewsRx correspondents, research stated, "We previously showed that blind rats whose vision was restored by gene transfer of Chlamydomonas channelrhodopsin-2 (ChR2) could only detect wavelengths less than 540nm because of the actionaction spectrum of the transgene product. Volvox-derived channelrhodopsin-1, VChR1, has a broader spectrum than ChR2."

More Content

All (17) | News (14) | Reports (0) | Blogs (2) | Audio/Video (1) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Data on Molecular Therapeutics Reported by Rese... [Published Industrial Info Financials - Sep 10 2014]
Data on Molecular Therapeutics Reported by Rese... [Published HispanicBusiness.com - Sep 10 2014]
Less pain, more gain [Published Drug Discovery News - Sep 10 2014]
uniQure Announces Results for the Second Quarte... [Published Virtual Strategy Magazine - Sep 02 2014]
Reports from Osaka University Provide New Insig... [Published Crawford Financial Planning - Aug 28 2014]
Reports from Osaka University Provide New Insig... [Published HispanicBusiness.com - Aug 28 2014]
Research Data from Tohoku University Update Und... [Published Wall Street Business Network - Aug 28 2014]
Research Data from Tohoku University Update Und... [Published HispanicBusiness.com - Aug 28 2014]
4-Aminopyridyl-Based CYP51 Inhibitors as Anti-... [Published Journal of Medicinal Chemistry - Aug 19 2014]
Research Leader Looks Beyond Genetic Mechanisms... [Published OncLive - Aug 12 2014]
Oncothyreon Announces Acquisition of Alpine Bio... [Published TickerTech.com - Aug 11 2014]
Oncothyreon Announces Acquisition of Alpine Bio... [Published PR Newswire: Financial Services - Aug 11 2014]
Ignyta Appoints Adrian Senderowicz, M.D., as Ch... [Published Investor's Business Daily - Aug 11 2014]
Ignyta Appoints Adrian Senderowicz, M.D., as Ch... [Published Benzinga.com - Aug 11 2014]
HERS Breast Cancer Foundation Event Honors Comm... [Published PRWeb - Apr 21 2014]
The Humor Code [Published Slate Magazine - Mar 27 2014]
Forbion Capital-backed uniQure completes IPO [Published PE Hub Blog - Feb 13 2014]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Oncothyreon Announces Acquisition of Alpine Bio... [Published PR Newswire: Financial Services - Aug 11 2014]
Oncothyreon to Leverage Alpine's Protocell Technology to Enable TargetedDelivery of Molecular Therapeutics for Serious DiseasesCompany to Hold Conference Call at 4:30 p.m. EDT TodaySEATTLE, WA, Aug. 11, 2014 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ONTY), ...
Forbion Capital-backed uniQure completes IPO [Published PE Hub Blog - Feb 13 2014]
Forbion Capital Partners -backed uniQure , which develops gene therapy products, has completed an initial public offering at a price of $17 per share on the NASDAQ . Jefferies and Leerink Partners acted as joint book-running managers and Piper ...
1

Audio/Video

sort by: Date | Relevance
The Humor Code [Published Slate Magazine - Mar 27 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.